Editorial: Sexual function in patients undergoing combination treatment with α1‐adrenoceptor antagonists and 5α‐reductase inhibitors – a step forward in a still‐open debate
Combination treatment with α1‐adrenoceptor antagonists and 5α‐reductase inhibitors (5ARIs) is recommended in men with moderate‐to‐severe LUTS and risk of disease progression 1, 2. These drugs can improve symptoms as well as urodynamic markers of BOO 3, 4. Despite the clinical benefits, the potential negative impact of these drugs on sexual function is of major concern, and may be cause […]